Analystreport

Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $45.00 price target on the stock.

Eiger BioPharmaceuticals, Inc.  (EIGR) 
Last eiger biopharmaceuticals, inc. earnings: 3/13 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.eigerbio.com